Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus.
Production of influenza vaccines requires a minimum of 6 months after the circulating strain is isolated and the use of infectious viruses. The hemagglutinin (protective antigen) of circulating influenza viruses mutates rapidly requiring reformulation of the vaccines. Our goal is to eliminate the risk of working with infectious virus and reduce significantly the production time. A cDNA fragment encoding the influenza virus A/Vietnam/1203/2004 (H5N1) HA gene was prepared using RT-PCR with viral RNA as a template. Recombinant HA (rHA) protein was produced in Escherichia coli and purified from isolated inclusion bodies by urea solubilization and Ni(+)-ion column chromatography. Vaccine candidates were prepared by treating the rHA with formalin, adsorption onto alum or with both. Mice were injected subcutaneously with candidate vaccines two or three times 2 weeks apart. Sera were collected 1 week after the last injection and antibody measured by ELISA and hemagglutination inhibition (HI). The highest antibody response (GM 449EU) was elicited by three injections of 15microg alum-adsorbed rHA. Dosages of 5microg of rHA formulated with formalin and alum, and 5microg alum-adsorbed rHA elicited IgG anti-HA of GM 212 and 177EU, respectively. HI titers, >or=40 were obtained in >or=80% of mice with three doses of all formulations. We developed a method to produce rHA in a time-frame suitable for annual and pandemic influenza vaccination. Using this method, rHA vaccine can be produced in 3-4 weeks and when formulated with alum, induces HA antibody levels in young outbred mice consistent with the FDA guidelines for vaccines against epidemic and pandemic influenza.
Biesova
Zuzana
Z
Program in Developmental and Molecular Immunity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, United States.
Miller
Mark A
MA
Schneerson
Rachel
R
Shiloach
Joseph
J
Green
Kim Y
KY
Robbins
John B
JB
Keith
Jerry M
JM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000534:Alum Compounds / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004926:Escherichia coli / Q000378:metabolism; D005260:Female; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics / Q000276:immunology*; D007074:Immunoglobulin G / Q000097:blood; D053124:Influenza A Virus, H5N1 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic; C109963:hemagglutinin, avian influenza A virus; C041524:aluminum sulfate
Infect Immun. 1991 Feb;59(2):625-30
1702767
J Infect Dis. 1978 Nov;138(5):618-24
712117
J Exp Med. 1964 Dec 1;120:1041-9
14238923
J Infect Dis. 2000 Mar;181(3):1133-7
10720541
N Engl J Med. 2005 May 5;352(18):1839-42
15872196
Vaccine. 2001 Feb 8;19(13-14):1732-7
11166898
J Virol. 2009 Mar;83(6):2553-62
19109379
Br Med Bull. 1979 Jan;35(1):35-8
367484
Ann N Y Acad Sci. 1992 Oct 13;665:320-33
1416613
Anal Biochem. 1981 Apr;112(2):195-203
6266278
Bull Hist Med. 2002 Spring;76(1):105-15
11875246
Dev Biol (Basel). 2003;115:97-104
15088780
Vaccine. 2001 May 14;19(25-26):3444-50
11348709
Virology. 2008 May 25;375(1):182-9
18308356
J Immunol. 1975 Aug;115(2):434-9
807637
Br Med Bull. 1979 Jan;35(1):39-46
367485
Vaccine. 2000 Sep 15;19(2-3):213-6
10930675
Nat Struct Mol Biol. 2009 Mar;16(3):265-73
19234466
Curr Top Microbiol Immunol. 2004;283:313-42
15298174
J Fam Pract. 2000 Sep;49(9 Suppl):S41-50
11032192
JAMA. 1982 Nov 19;248(19):2478-80
7131703
Clin Vaccine Immunol. 2009 Apr;16(4):558-66
19225073
J Med Virol. 2008 Nov;80(11):1972-83
18814259
PLoS Med. 2005 Dec;2(12):e359
16255619
Br Med Bull. 1979 Jan;35(1):69-75
367490
J Virol. 2008 Jul;82(13):6200-8
18417563
Dev Biol Stand. 1975;28:253-72
47824
J Hyg (Lond). 1972 Dec;70(4):767-77
4509641
Infect Immun. 1993 Sep;61(9):3678-87
8359890
Br Med Bull. 1979 Jan;35(1):57-63
367488
J Infect Dis. 1995 Jun;171(6):1387-98
7769272